Prospective, Randomized, Multicenter, Controlled Trial of a Bioartificial Liver in Treating Acute Liver Failure

Demetriou, Achilles A.; Brown, Robert S.; Busuttil, Ronald W.; Fair, Jeffrey H.; McGuire, Brendan M.; Rosenthal, Philip; Esch, Jan Schulte Am; Lerut, Jan; Nyberg, Scott L.; Salizzoni, Mauro; Fagan, Elizabeth A.; Hemptinne, Bernard de; Broelsch, Christoph E.; Muraca, Maurizio; Salmerón, Joan Manuel; Rabkin, John M.; Metselaar, Herold J.; Pratt, Daniel S.; Mata, Manuel de la; McChesney, Lawrence; Everson, Gregory T.; Lavin, Philip T.; Stevens, Anthony C.; Pitkin, Zorina; Solomon, Barry A.

doi:10.1097/01.sla.0000124298.74199.e5

Cited by 598 publications

(311 citation statements)

References 15 publications

Supporting

Mentioning

296

Contrasting

Unclassified

Order By: Relevance

“…18,22,23 On admission, extracorporeal liver support involving a molecular adsorbent recycling system 24,25 or a bioartificial liver was initiated in 3 patients. [25][26][27] After LT, all patients received immunosuppressive therapy according to the standard practice of our center. In the HIV-positive patient who underwent LT, antiretroviral HIV therapy was reintroduced 2 weeks after transplantation.…”

Section: Patient Managementmentioning

confidence: 99%

Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver transplantation

et al. 2010

View full text Add to dashboard Cite

The standard antitubercular treatment (ATT), which consists of isoniazid (INH), rifampicin (RIF), ethambutol, and pyrazinamide (PZA), is the best available treatment for tuberculosis (TB). However, the hepatotoxicity of INH and PZA can be severe, and even after drug withdrawal, patients may require liver transplantation (LT). In these cases, the strategy for the treatment of TB is poorly defined. Between 1986 and 2008, 14 patients presented at our department with severe hepatitis secondary to INH and PZA treatment. Four of these patients were immunosuppressed: 2 after renal transplantation and 2 because of human immunodeficiency virus infection. In seven of the 14 patients an alternative ATT was begun on admission, which was well tolerated. Hepatitis improved spontaneously in 5 patients, and alternative ATT was continued for 9.3 6 4.2 months; 1 patient deteriorated and underwent LT, and 1 patient died. ATT was stopped definitively in 2 patients. Six patients required urgent LT, and alternative ATT was started after transplantation and was successful. Five patients receiving RIF had an episode of acute rejection. In conclusion, hepatitis secondary to ATT can be successfully treated with alternative anti-TB regimens. The use of RIF in LT patients may lead to acute rejection. RIF should therefore be avoided in these patients.

show abstract

Section: Patient Managementmentioning

confidence: 99%

Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver transplantation

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Thus, there are similarities between the RFB and the anatomy of hepatic lobules ( Figure 1B) [2,7] . Because of the easy availability, recent reports point out a clinical use of BAL systems that utilize animal cells [8,9] . Fetal porcine hepatocytes have a high proliferative potential in vitro.…”

Section: Introductionmentioning

confidence: 99%

Hepatic reconstruction from fetal porcine liver cells using a radial flow bioreactor

Ishii¹,

Saito²,

Marushima³

et al. 2008

WJG

View full text Add to dashboard Cite

show abstract

“…14,15 Later, two distinct strategies evolved, one aimed at the development of cell-based bioartificial liver support systems, 16 the other focussing on cell-free medical devices. 17 Forerunners in the development of bioartificial liver support systems that made it into systematic clinical tests were the Berlin Extracorporeal Liver Support System, consisting of a three-dimensional, hollow fiber perfusion device containing primary porcine or human liver cells, 18 the Extracorporeal Liver Assist Device, comprised of a hollow fiber bioreactor filled with human hepatoma cells (C3A), 19,20 and the Bioartificial Liver, 21 a complex device combining plasma separation and subsequent processing by a carrier-based porcine hepatocyte culture and coated charcoal. Currently, all bioartificial, cell-based liver assist devices are still undergoing pre-marketing clinical trials and are not available for the critical care therapist on a commercial basis; this chapter will not focus on them.…”

Section: Technologymentioning

confidence: 99%

Extracorporeal liver support

Stange

2011

Organogenesis

View full text Add to dashboard Cite

Prospective, Randomized, Multicenter, Controlled Trial of a Bioartificial Liver in Treating Acute Liver Failure

Abstract: This is the first prospective, randomized, controlled trial of an extracorporeal liver support system, demonstrating safety and improved survival in patients with fulminant/subfulminant hepatic failure.

Cited by 598 publications

References 15 publications

Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver transplantation

Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver transplantation

Hepatic reconstruction from fetal porcine liver cells using a radial flow bioreactor

Extracorporeal liver support

Contact Info

Product

Resources

About